CRSP Stock Predictions
| Recent CRSP Stock Price | CRSP Stock Predictions | |
| $54.71 |  +151.87% |
$137.80 |
| Recent CRSP Analyst Ratings Breakdown, Making CRSP Stock Predictions | ||||
|---|---|---|---|---|
| Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
| Strong buy ratings: | 12 | 12 | 12 | 13 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 3 | 3 | 3 | 3 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 1 | 1 | 1 | 1 |
| Average rating: | 1.63 | 1.63 | 1.63 | 1.59 |
For the CRSP stock predictions from the analysts covering CRISPR Therapeutics AG, we have collected all of the individual CRSP stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 15 different analysts covering CRSP (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since CRSP stock predictions may vary widely, another useful metric to consider is the median CRSP stock prediction, which represents the price at which half of the analysts
made CRSP stock predictions that were higher and half made CRSP stock predictions that were lower. This makes for a different take on the CRSP stock predictions out there, as compared to average or mean.
And that median across all the individual CRSP stock predictions was: $143.0 as of 2022-05-24.
The very highest of the CRSP stock predictions for one year price target was $220.0, while the very lowest of the CRSP stock predictions in the analyst group was
$52.0 (with a standard deviation of $41.524). Get the latest Zacks research report on CRSP — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
• WSBF Stock Predictions
• MEC Stock Predictions
• VCRA Stock Predictions
• ONE Stock Predictions
• INVA Stock Predictions
• VAC Stock Predictions
• ALE Stock Predictions
• SXC Stock Predictions
• MFGP Stock Predictions
|
|||||||||
|
|
|
|
|
|
Free CRSP Email Alerts:
Avg. Broker Rec.
 
|
Buy (3.37 out of 4) 44th percentile
(ranked lower than approx. 56% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|
|
